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Coronary angiography is an invasive diagnosis 
method which is accepted as a golden standart both 
to diagnose coronary heart diseases and to guide 
the treatment nowadays. It has a vital significance 
to realize the complications occuring during the 
procedure or in the post-process term and to deter-
mine on the treatment as soon as possible in case 
of necessity for coronary angiography. It is possible 
to see contrast induced nephropathy (CIN) because 
of the involved contrast media after the process. The 
most important possible non-idiosyncrasic reaction 
is contrast induced nephropathy after using contrast 
media through a intravascular way [1]. Nephropat-
hy,  which develops as a result of the increase in the 
serum creatinine without considering the need for 
a clinical symptom or hemodialysis, is defined as 
contrast induced nephropath [2].
In many institutions, the risk analysis is not 
applied to the patients and there is not a consistent 
practice for CIN. It is known that the serum creatini-
ne value is not checked before the procedure and 
48 hours after the implementation regularly in the 
patients given contrast media. If the risky patients for 
CIN are detected via attentive clues and preventing 
procedures are standartized and made effective, an 
important opportunity is gained to decrease the rate 
of mortality and morbidity. It is detected in a research 
taking place in a radiology clinic that only 20% of the 
patients and approximately 60% of the patients in 
the condition of diabetes which is a high risk for CIN 
were checked for the serum creatinine value before 
the contrast media procedure. And it indicates that 
many patients who have high risk are not detected 
before the procedure. It is possible to detect  this 
risky group at least by asking some simple questions 
and laboratory practice and to follow-up them after 
the procedure. A slight increase in the serum creati-
nine level may increase the patient’s mortality and 
mobility. Detecting the risky patients and fulfilling 
profilactic treatment (e.g prehydration) will decrease 
the possible problems [3-6]. 
We have aimed to make a research for the risk 
factors of CIN in the patients undergoing coronary 
angiography and the ones in the intensive care unit 
with the diagnosis of acute coronary syndrome; to 
classify the patients according to their risk factors 
and to detect the frequency of the CIN. Consequ-
ently, the patients who have a risk for CIN will be 
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detected by using risk scoring tables and the sus-
ceptibility to take the protective measures will be 
increased by applying protective treatment (acute 
renal failure, the need for dialysis, staying in hospital 
and increase in mortality).
Material and method
93 patients who lined in TC Bașbakanlık Bezm-i 
Alem Valide Sultan Vakıf Gureba Hospital Coronary 
Intensive Care Unit  (KYBÜ) with the diagnosis of 
acute coronary syndrome between November 2008 
and 2009 were involved in our study. The diabetic, 
the ones in cardiogenic shock and who have crucial 
renal and hepatic failures, the ones who did not 
apply us for the urea and creatinine measurement 
on the third day of the procedure were not involved 
in the study. The analysis of the patients were taken 
by considering the risk factors. The level of glucose, 
urea, creatinine, uric asid, hemoglobin A1c, C-reacti-
ve protein; liver function tests, tyroid function tests, 
lipid profile, estimated glomerular filtration speed 
(eGFR), full urinanalysis, hemogram were checked 
and the level of urea and creatinin were measured 
on the third day. Whether they took thrombotic 
treatment after the acute coronary syndrome, they 
smoke, were diagnosed as hypertension or diabetes 
mellitus (DM) or not were recorded. Cardiac failure 
was searched, the ones who have a background of 
Class-3 and Class-4 according to the New York Heart 
Committe and/or pulmonary edema experience 
were involved in scoring. According to the World 
Health Organisation (WHO) criteria, the level of he-
matocrit is accepted as anemic in men <39% and in 
women <36%. Estimated glomeruler filtration speed 
was calculated via MDRD formula. In the light of 
these findings, the patients were classified according 
to the risk scoring table prepared by Mehran and his 
collgues. The frequency of the patients who have 
low, middle and high risk in the whole patient gro-
up were detected. On the third day of the coronary 
angiography, the level of urea and creatinine were 
measured and the frequency and the percentage of 
the contrast nephropathy development were estima-
ted. The one who developed contrast nephropathy 
were sent to nephrology polyclinic and their follow-
ups were done here. Under the light of the findings, 
the influence of gender, diabetes, anemia, the level 
of eGFR, smoking, urea level above 50 mg, creatini-
ne level above 1mg/dl, cholesterol-LDL-triglyceride 
level, age above 75 were studied. The meaningful 
data was shown in the tables.
This study was approved by Bezm-i Alem Valide 
Sultan Vakıf Gureba Hospital Local Ethic Board. Each 
patient was informed about the study and their 
approvements were taken with their signatures. 
For descriptive statics, average deviation ± (mini-
mum and maximum values) and  cardinal numbers 
(percentage); for group comparisons, Students t, 
Mann-Whitney U, Fisher exact tests and ki-kare 
tests were used. Besides, Odd’s ratio (OR) and 95% 
confidence interval (95% CI) values were estimated. 
Statistical analysis was made with SPSS for Windows 
12.0 programme and if the p value is below 0.05, it 
is accepted as meaningful statistically.
Findings
It was detected that 93 patients included into 
the study consisted of 51 males (54.8%), 42 femaless 
(45.2%); 22 patients suffering from contrast induced 
nephropath (CIN) consisted of 13 males (59.15), 9 
femaless (40.9%). It is found out that the gender 
does not have a meaningful influence on CIN de-
velopment statistically (p=0.831) (table 1). The age 
average is estimated as 62.51±10.81 (37-90). The age 
average in the cases with contrast nephropathy is 
69.05±10.30 and in the contrary case the age ave-
rage is .60.48±10.20 (p=0.001). It is seen that 66.7% 
of the patients who are above 75 and 19.0% of the 
patients who are 75 and below 75 suffered from CIN 
(p=0.005). Diabetes mellitus (DM) was found in 44 
patients (47.3%) and 15 of these patients (34.1%) 
had CIN. 49 patients (52.7%) were not diagnosed 
with diabetes and CIN was detected in 7 of them 
(14.3%) (p=0.046). Anemia was detected in 43 
patients (46.2%) and CIN developed in 17 of these 
patients (39.5%). Anemia is not determined in 50 
patients (53.8%) and CIN developed in 5 (10%) of 
these patients (p=0.01). The eGFR level of the pati-
ents were measured and it was seen that the result 
was 40-60 ml/min/1.73 m2 in 13 (14%) patients. CIN 
was found in 5 (38.5%) of these patients (p=0.316). 
The average creatinine level of the involved patients 
were detected as 0.85±0.21 (0.5-1.4). In the cases 
developing CIN, the level was found as 0.82±0.26 
and in the contrary cases the level was found as 
0.86±0.19 (p=0.165). There were 19 patients (20.4%9) 
whose creatinine levels were above 1 mg/dl and six of 
them (31.6%) developed CIN. There were 74 patients 
(79.6%) whose creatinine levesl were under 1 mg/dl 
and 16 of them (21.6%) developed CIN (p=0.543). The 
average urea measurement level of the patients was 
40.34±14.84 (18-78) and this number was 40.45±14.57 
in the patients who developed CIN, 40.31±15.03 in 
the ones who did not develop CIN (p=0.867). Of 22 
(23.7%) patients whose urea level was above 50 ml, 
six of them (27.3%) developed CIN.
Of 71 patients (76.3%), 16 of them (22.5%) 
developed CIN (p=0.865). With regard to smoking, 
it was found that 63 patients (67.7%) had a habit of 
smoking and 30 patients (32.3 %) did not. In both of 
the groups, 11 patients (17.5%; 36.7%) developed 
CIN (p=0.076) (table 1). 
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Table 1 
The influence of risk factors on the development of contrast induced nephro-
pathy
CIN n (%)
Available Not available P OR % 95 CI
Gender
Femaless 33 (%78.6)  9 (%21.4) 0.831 0.797 0.302-2.102
Males 38 (%74.5) 13 (%25.5)
Age
75 and below 75 68 (%81.0) 16 (%19.0) 0.005 8.50 1.917-37.680
Above 75 3 (%33.3) 6 (%66.7)
Diabetes Mellitus
Not available 42 (%85.7) 7 (%14.3) 0.046 3.103 1.125-8.558
Available 29 (%65.9) 15 (%34.1)
Anemia
Not available 45 (%90.0) 5 (%10.0) 0.001 5.885 1.942-17.818
Available 26 (%60.5) 17 (%39.5)
eGFR
0 63 (%78.8) 17 (%21.3) 0.316 2.316 0.671-0.7997
2  8 (%61.5)  5 (%38.5)
Creatinine
1 mg/dl and below 58 (%78.4) 16 (%21.6) 0.543 1.673 0.549-5.100
1 mg/dl and above 13 (%68.4)  6 (%31.6)
Urea
50 ml and below 55 (%77.5) 16 (%22.5) 0.865 1.289 0.433-3.838
50 ml and above 16 (%72.7)  6 (%27.3)
Smoking
Not available 19 (%63.3) 11 (%36.7) 0.076 0.365 0.136-0.981
Availabe 52 (%82.5) 11 (%17.5)
Total 71 (%76.3) 22 (%23.7)
The average biochemical values of the patients were detected 
as cholesterol 186.9±46.702 (100-364), LDL 117.83±47.094 (45-391), 
triglyiceride 128.19±68.463 (35-398), uric acid 5.617±1.71 (2.3-9.9). The 
average of the CIN developed patients and the non-developed ones 
and their p values were shown in table 2. It is discovered that the level 
ofcholestrol, LDL, triglycreide and urșc aciddo not have an influence 
on the development of CIN. Estimanting the risk level of the patients, 
risk scoring table of Mehran and his collegues was used [11]. The risk 
groups and the percentage of the CIN development were shown in 
table 3. As seen via these findings, CIN development in low risk group 
is 12.3%, in middle risk group is 38.70% and in high risk group is 60%. 
Considering all of the patients, CIN was seen in the rate of 23.7%.
Table 2 
The influence of cholesterol, LDL, triglyceride, uric acid levels on contrast in-
duced nephropathy (CIN)
CIN N Average Standard deviation P
Cholesterol Not available 71 185.06 43.30 0.632
Available 22 192.86 57.06
LDL Not available 71 116.73 48.89 0.418
Available 22 121.36 41.57
Triglyceride Not available 71 123.39 61.32 0.464
Available 22 143.68 87.57
Uric Acid Not available 71 5.55 1.72 0.483
Available 22 5.82 1.67
N – number of the people, LDL – low density lipoprotein.
Table-3 
The percentage of patients’ risk groups and 
development of contrast induced nephro-
pathy (CIN)
CIN n (%)
Not available Available 
Risk 
level
Low 50 (%87.7) 7 (%12.3)
Middle 19 (%61.3) 12 (%38.7)
High  2 (%40.0)  3 (%60.0)
Total 71 (%76.3) 22 (%23.7)
Discussion
Contrast induced nephropathy is 
the common third reason of  acute re-
nal failure which acquired in hospital 
setting [1, 2, 7]. The patients who have 
a high risk of contrast induced nep-
hropathy are either the one who ve 
renal function disorders or diabetes or 
congestive heart failure. The other risk 
factors are growing old (>75), being 
a femaless, dehydration, anemia and 
using too muh contrast media.  
Preexisting renal function di-
sorder and diabetes are accepted as 
the most significant risk factors. Due 
to the synergic influence of these 
two factors, nephropathic patients 
with diabetes mellitus constitute 
the most risky group  [1, 6, 8-10]. 
In a study made by Parfrey and his 
collegues, it is found out that the CIN 
incidence in non-diabetic normal 
renal functioning patients is 2%, it 
is 7 % in the patients with type DM 
1 and not having a renal failure, and 
it is 50% in patients who have type 1 
DM and renal failure [4]. 15 (34.1%) of 
the 44 diabetic patients were found to 
develop CIN and it was found mea-
ningful p:0.046. Previous renal failure 
is a certain reason of CIN. In a study 
made by Chen and his collegues, CIN 
incidence was found meaningfully 
higher in a group of which creatinine 
level is anormal (serum kreatin≥1.5 
mg/dl)  than the group which had a 
normal level (37.68%, 6.25%, p<0.001) 
[8]. In the study, a big difference could 
not be found considering the CIN 
development among the patients 
whose creatinine level were 0,5-1 ve 
1-1,5. In many studies, it was indicate 
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that the development of incidence of CIN increased 
in the patients who were above 75. Besides, it was 
seen that CIN developed in the 66.7 % of the patients 
who were above 75 (p:0.005). 
The role of gender on CIN  is contraversial. 
Studies yield different results [6,10]. A meaningful 
difference could not be found between the males 
and femaless patients (p:0.83). In a study on 9726 
patients undergoing to percutaneous coronary in-
tervention made by Mehran and his collegues, 21% 
of the anemic patients developed CIN [11]. 17 of the 
43 anemic patients (39.5%) developed CIN (p:0.001). 
The relation between smoking and CIN was looked 
for, but a meaningful realtion could not be found 
(p:0.076). Moreover, the relation between levels of 
urea, creatinine, cholesterol, LDL, triglyceride, uric 
acid and KMN was studied, but a meaningful realtion 
could not found similarly.
The primary approach to prevent nephropathy 
resulted from contrast media is to observe patients’ 
present features systematically and scoring the risk 
grades. Risk scoring systems were suggested to 
foresee frequency of CIN develeopment after per-
cutaneous coronary intervention (PCI). 
Lisstro F. and collegues classified CIN risk de-
velopment as low, middle and high risk groups [12]. 
Mehran and his collegues identified eight indepen-
dent risk predictors according to the rsik scoring 
system based on the prospective data gained from 
9726 patients undergoing PCI. 
There was detected a linear relation  betwe-
en the total number of these risk factors and CIN 
frequency (șekil-1) [11]. CIN developed in 7 of 57 low 
risk patients (12.3%), 12 of 31 middle risk patients 
(38.7%) and 3 of 5 high risk patients. Totally, 22 out 
of 93 patients (23.7%) developed CIN. Looking at 
Mehran and his collegues’ study, it is seen that CIN 
developed in the rate of 7.5% in low risk group, 14% 
in middle risk group, 26.1% in high risk group and 
57.3% in very high risk group. 
In total, 13.1% of the patients developed CIN. 
The angiography was given to the patients in the ou-
tern services where they had been sent to. In spite of 
the suggestion, no protective procedure was applied 
to the patients before or after the procedure. 
Whereas Mueller and his collegues detected a 
CIN frequency of 0.6% in a group which was hydrated 
with isotonci liquid, they found the CIN frequency as 
2.7% in a group which was given semi-isotonic liquid 
in a study made with 1620 patients [13]. Hydrating 
the patients to prevent the development of  CIN is 
definitely necessary.
In a study,it was found that the mortality in ho-
spital is 22% with the patients developing CIN [14]. 
The same measurement is 21.4% after using contrast 
media in a different study made by Marenzi and his 
collegues (15). Permanent hemodialysis rate may 
increase to 12% with the high risk patients. 
As a result of the study on 1826 patients un-
dergoing to percutaneous intervention  made by 
McCullough and his collegues, the frequency of 
CIN requiring hemodialysis is <1%, and in hospital 
mortality is 35.7%, survival for two years is 18% [1]. 
This rate with the patients who did not develop CIN 
is just 1.4%. The mortality rate in the first and fifth 
years of the patients who developed contrast indu-
ced nephropathy and left the hospital alive are 12.1% 
and 44.6%. Although these rates do not directly 
reflect the prognosis resulted from using contrast 
media, it should be considered that preventing the 
development of contrast induced nephropathy, 
which is an important element for the development 
of acute renal failure, is a significant factor to heal 
the prognosis.
Conclusion
CIN is one of the most important reasons of 
acute renal failure developing in a hospital setting. 
Radiologic applications which do not require con-
trast media should be given priority at the first 
place, especially with the highest risk patients who 
suffer from renal failure (serum kreatinin>1.5 mg/
dl). If using contrast media is absolutely necessary, 
then, nephrotoxic medicine has to be suspended, 
losing water and salt should be avoided and low 
dose osmolar non-ionic  contrast media should be 
prefered. 
Liquid treatment, the most valid and presently 
approved method used to prevent contrast induce 
nephropathy is a prophylactic procedurewhich is 
used very often since it is easy and cheap. CIN can be 
mostly prevented by enlarging the volume  through 
giving 0.45% saline infusion – the urine level sho-
uld be  minimum 75 ml/min – 12 hours before the 
procedureand maintaining it for 12-24 hours after 
the procedure  to the high risk patients undergoing 
the procedure requiring high dose contrast media 
such as patients who have previously known renal 
failure, old patients, having dehydration problem 
and having multiple risk factors in particular. Renal 
functions of the high risk patients have to be moni-
torized after the contrast procedurefor 48-72 hours. 
Since incidence rate is low, the patients who do not 
have risk factors do not have to be monitorized. The 
first thing to be done is to scoring the risk in order 
to determine the high risk patients in the process of 
preventing the development of CIN and treament. 
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